cat preparing to eat food with senvelgo solution added
cat preparing to eat food with senvelgo solution
Senvelgo packshot

Introducing Senvelgo®

Senvelgo® is a convenient, once-daily oral solution that makes treating feline diabetes simple for vets, nurses, cats and their owners.

cat outside, with a weighing scale icon in the top left
Simple dosing according to bodyweight
cat looking at a bowl of food, with a "no drop" icon in the top left
No risk of symptomatic hypoglycaemia
cat lying in a cat bed, with a droplet icon including a number one, in the top left
Glycaemic control can be achieved within a week1, 2

The breakthrough for feline diabetes

Choosing Senvelgo® means you can now treat diabetes without injecting insulin.

cat getting pet on the neck by a human

Feline diabetes is a growing concern

Diabetes currently affects approximately 1 in 200 cats.3,4

With 1 out of 3 cats believed to be overweight, and obesity being a risk factor for feline diabetes, that number may be expected to grow.5,6

Risk factors

All cats are potentially susceptible to diabetes, with the vast majority suffering from a resistance to insulin (similar to type 2 diabetes in people).

Risk factors include:

  • Icon of a drop of senvelgo

    Obesity

  • Icon of a drop of senvelgo

    Increased age

  • Icon of a drop of senvelgo

    Lack of physical activity

  • Icon of a drop of senvelgo

    Steroid therapy

  • Icon of a drop of senvelgo

    Neutering

  • Icon of a drop of senvelgo

    Genetics and breed predisposition

  • Icon of a drop of senvelgo

    Concomitant disease (e.g. other hormonal diseases)

Senvelgo® gives you the power to save lives with the simplicity of this innovative, once-daily oral solution.

Common challenges and concerns

Diabetes is a challenging condition that triggers medical and emotional concerns in vets, nurses and cat owners alike. Some of the most common concerns include:7,8,9

Vet & nurse concerns

  • icon displaying a wave

    Difficulties obtaining rapid and adequate control

  • icon displaying a handshake

    Getting owners to agree to treatment

  • icon displaying a down arrow

    Hypoglycaemia

  • icon displaying a thumbs up

    Insulin dose optimisation

  • icon displaying a happy cat

    Quality of life

Owner concerns

  • icon displaying a thumbs down

    Fear of giving injections

  • icon displaying an airplane

    Lifestyle impact

  • icon displaying a worried person

    Worry about hypoglycaemia

  • icon displaying a pound sign

    Cost

  • icon displaying a group of people

    Availability of family members to administer injections

  • icon displaying a sad cat

    Anticipated pet reaction to injections

Easing the burden of diabetes

The complexity and time required to treat diabetes can lead to compliance issues, treatment abandonment, and even the tragic loss of patients’ lives.7  As a convenient, once-daily oral solution, Senvelgo® can help change that.

Diagnosing a cat with diabetes can be a stressful moment for clinics and cat owners alike. While insulin, thankfully, made feline diabetes a treatable condition, it still involves:

  • Icon of a drop of senvelgo

    Twice-daily injections and significant lifestyle changes for the owner

  • Icon of a drop of senvelgo

    Training the owners to correctly handle and inject insulin

  • Icon of a drop of senvelgo

    Finding the right dose and time-consuming blood glucose curves

  • Icon of a drop of senvelgo

    The ongoing risk of hypoglycaemic events

Senvelgo® eliminates these concerns, helping make it possible for your client and patient to enjoy a normal quality of life, despite this disease.

cat looking at a food bowl
cat looking at a food bowl

Senvelgo® is a breakthrough product for feline diabetes

  • A convenient, once-daily oral solution.
  • Developed as a collaboration between Boehringer Ingelheim’s animal health and human diabetes experts.
  • Senvelgo® contains velagliflozin: a highly selective inhibitor of sodium glucose co-transporter 2 (SGLT-2).
  • SGLT-2 is predominantly expressed in the proximal tubules of the kidney which is responsible for around 90% of glucose reabsorption.
  • Senvelgo® only has a minor impact on SGLT-1 transporter, which is primarily expressed in the small intestine and the distal part of the proximal tubules of the kidney where it is responsible for 10% of glucose reabsorption.
  • Senvelgo® therefore blocks most glucose reabsorption by inhibiting SGLT-2, causing excretion of excess glucose and reducing hyperglycaemia. Sufficient glucose is still reabsorbed via SGLT-1 which prevents clinical hypoglycaemia.
How Senvelgo® works

References

  • 1. Niessen, S. J. M. et al. (2022) Once daily oral therapy for feline diabetes mellitus: evaluation of SGLT-2 inhibitor velagliflozin as stand-alone therapy compared to insulin injection therapy in diabetic cats. Journal of Veterinary Internal Medicine 36, 2512–2513.

  • 2. Sparkes, A. H. et al. (2015) ISFM Consensus Guidelines on the Practical Management of Diabetes Mellitus in Cats. J Feline Med Surg 17, 235–50.

  • 3. McCann, T., et al. (2007) Feline diabetes mellitus in the UK: the prevalence within an insured cat population and a questionnaire-based putative risk factor analysis. J Feline Med Surg 9, 289–9.

  • 4. O’Neill, D., et al. (2016) Epidemiology of Diabetes Mellitus among 193,435 Cats Attending Primary-Care Veterinary Practices in England. J Vet Intern Med 30, 964–72.

  • 5. Rand J, Gottlieb, SA. Feline diabetes mellitus. Textbook of Veterinary Internal Medicine, 8th edition. Ettinger SJ, Feldman EC and Cote E, eds. Elsevier, Missouri. 2017;1781-1795.

  • 6. 2018 Summary of the Veterinary Clinic: Pet Obesity Prevalence Survey & Pet Owner: Weight Management, Nutrition, and Pet Food Survey. Available at:
    https://petobesityprevention.org/2018.

  • 7. Niessen, S. J. M. et al. (2017) The Big Pet Diabetes Survey: Perceived Frequency and Triggers for Euthanasia. Vet Sci 4, 27.

  • 8. Diabetes in Cats: Quantitative market research study. Proprietary presentation, July 19, 2021. Kynetec; St. Louis, MO, on behalf of Boehringer Ingelheim.

  • 9. Niessen, S. J. M. et al. (2010) Evaluation of a quaility-of-life tool for cats with diabetes mellitus. J Vet Intern Med 24, 1098-105.

  • 10. Behrend, E. N. et al. (2023) Velagliflozin, an SGLT2 Inhibitor, as a once-daily, oral solution, stand-alone therapy for feline diabetes mellitus. Oral abstract presentation, 2023 ACVIM Forum, Pennsylvania, Jun 15-17.

  • 11. Niessen, S. J. M. et al. (2023) Efficacy and safety of once daily oral sodium-glucose co-transporter-2-inhibitor velagliflozin compared to twice daily insulin injection therapy in diabetic cats. Oral abstract presentation, 2023 ECVIM-CA Forum, Barcelona, Sept 21-23.

  • 12. VMD. Summary of Product Characteristics (SPC): Senvelgo® 15mg/ml oral solution for cats (velagliflozin). Veterinary Medicines Directorate, UK.

  • 13. CM Research (2022) Small animal vets UK April 2022. Syndicated Sales Rep Survey.

Welcome to the Senvelgo® vet website

Senvelgo® is a prescription only medicine. This website is only intended for Great Britain residents who are veterinary professionals over the age of 18 and employed by or working in vet practices in Great Britain.

Please choose one of the following options to continue:

I am a veterinary professional I am an owner of a cat that has been prescribed Senvelgo® I am neither a veterinary professional nor the owner of a cat that has been prescribed Senvelgo®